Market closed
Zentalis Pharmaceuticals/$ZNTL
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Ticker
$ZNTL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
166
ISIN
US98943L1070
Website
ZNTL Metrics
BasicAdvanced
$86M
-
-$2.33
1.80
-
Price and volume
Market cap
$86M
Beta
1.8
52-week high
$13.00
52-week low
$1.01
Average daily volume
792K
Financial strength
Current ratio
7.322
Quick ratio
7.133
Long term debt to equity
11.737
Total debt to equity
12.649
Management effectiveness
Return on assets (TTM)
-23.86%
Return on equity (TTM)
-42.83%
Valuation
Price to revenue (TTM)
1.255
Price to book
0.25
Price to tangible book (TTM)
0.25
Price to free cash flow (TTM)
-0.494
Growth
Earnings per share change (TTM)
-47.77%
3-year earnings per share growth (CAGR)
-14.39%
What the Analysts think about ZNTL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Zentalis Pharmaceuticals stock.
ZNTL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ZNTL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ZNTL News
AllArticlesVideos
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
GlobeNewsWire·24 hours ago
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Zentalis Pharmaceuticals stock?
Zentalis Pharmaceuticals (ZNTL) has a market cap of $86M as of May 15, 2025.
What is the P/E ratio for Zentalis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Zentalis Pharmaceuticals (ZNTL) stock is 0 as of May 15, 2025.
Does Zentalis Pharmaceuticals stock pay dividends?
No, Zentalis Pharmaceuticals (ZNTL) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Zentalis Pharmaceuticals dividend payment date?
Zentalis Pharmaceuticals (ZNTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) has a beta rating of 1.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.